Ceftriaxone & Sulbactum Injection

(Ceftriaxone & Sulbactum Injection)

COMPOSITION:

VICEF-S 1.5 gm	VICEF-S 750mg	VICEF-S 375mg
Each Vial contains	Each vial contains	Each film coated tablet contains
Sulbactum 0.5mg	Sulbactum 250mg	Sulbactum 125mg
Ceftriaxone Sodium 1gm	Ceftriaxone 500mg	Ceftriaxone 250mg

INTRODUCTION:

VICEF-S is a combination of Sulbactum Sodium and Ceftriaxone Sodium available as dry powder for reconstitution. Ceftriaxone sodium is a sterile, semi synthetic, broad spectrum cephalosporin antibiotic for intravenous or intramuscular administration.

MECHANISM OF ACTION:

The anti bacterial component of VICEF-S is due to the inhibition of cell wall synthesis attained by the Cefiriaxone has a high degree of stability in the presence of Beta-Lactamases both penicillinases and cephalosporinases of gram-negative and positive bacteria. But chromosomaHy mediated enzymes though less common can be included in some strains of Kiebsiella, enterobacter and serratiaspecies.

Sulbactum in VICEF-S is a potent, highly specified inhibitor of a wide variety of beta lactamases produced by common gram-negative and gram-positive aerobes and anaerobes. by forming a protein complex with beta — lactamases, sulbactum irreversibly blocks their destructive hydrolytic activity. Thus , the fill potential of Ceftriaxone against Enterobacter and Pseudomonas speciesis restored by the addition of sulbactum. The combination of sulbactum and cefiriaxone sodium is active all the organisms sensitivity of Ceftriaxone. In addition, it demonstrate synergistic activity (reduction in minimum inhibitory concentration for the combination versus those of each component) in a variety of organisms.

INDICATIONS:

VICEF-S is indicated for the treatment of the following infections when caused by susceptible bacteria:

·         Lower Respiratory Tract infections

·         Acute Bacterial Otitis Media

·         Skin & Skin Structure Infections

·         Urinary Tract Infections (Complicated and UnComplicated)

·         Pelvic inflammatory Disease

·         Bacterial Septicemia

·         Bone and Joint Infections

·         Intra - Abdominal Infections

·         Meningitis

·         Sexually transmitted diseases

·         Surgical Prophylaxis

The prospective administration of VICEF-S may reduce the incidents of postoperative infections in patients undergoing surgical procedures

DOSAGE AND ADMINISTRATION:

VICEF-S may be administrated intravenously or Intramuscularly.

ADULTS:

The usual adults daily dose (in terms of Cefiriaxone) is 1-2 gms given once a day (or in equally divided doses twice a day ) depending on the type and severity of infection . The total daily doses should not exceed 4 gms. Dosage regimen of VICEF-S 1.5 should be adjusted in patients with marked decrease in renal function (creatinine clearance of less than 3Oml/min) to compensate for the reduced clearance less than 15ml/min should receive a maximum of 500 rng Sulbactum every 12 hours (Maximum dosage of I gm of Sulbactum)

PEDIATRIC PATIENTS:

For the treatment of skin and skin structure infections, the recommended total daily dose (in terms of cefiriaxone)is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 1 gms. For the treatment of acute bacterial otitis media, a single intramuscular dose (in terms of ceftriaxone) of 50mg/kg (not to exceed I gm) is recommended.

For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose (in terms of cefiriaxone) is 50 to 75 mg/kg given in divided doses every 12 hours. The total daily dose (in terms of ceftriaxone) should not exceed 2 gms.  In the treatment of meningitis, it is recommended that the initial therapeutic dose (in terms of ceftriaxone) be 100mg/kg (not to exceed 4 gms). The daily dose (in terms of ceftriaxone) may be administrated once a day (or in equally divided doses every 12 hours). The usual duration of the therapy is 7 to 14 days . Generally ceftriaxone therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared . The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required.

When treating infections caused by Streptococcus pyogenes , therapy should be continued for at least 10 days. No dosage adjustment is necessary for patients with impairment of rental or hepatic function; however blood levels should be monitored in patients with severs renal impairment (e.g. Dialysis Patients) and in patients with both renal and hepaticdys functions.

COMPETITIVE BRANDS:

Kefttragard Inj                        (IPCA)

Monobact Inj              (Zuventus)

Xtum                           (Shreya)

PRESCRIBING DOCTORS:

All Doctors